In-hospital Outcome of Patients with Culture-confirmed Tuberculous Pleurisy: Clinical Impact of Pulmonary Involvement
Overview
Affiliations
Background: Outcomes for hospitalized patients with tuberculous pleurisy (TP) have rarely been reported, and whether or not pulmonary involvement affects outcomes is uncertain. This study aimed to analyze the in-hospital mortality rate of culture-confirmed TP with an emphasis on the clinical impact of pulmonary involvement.
Methods: Patients who were hospitalized for pleural effusion (PE) of unconfirmed diagnosis and finally diagnosed as TP were identified. We classified them according to the disease extent: isolated pleurisy (isolated pleurisy group) and pleurisy with pulmonary involvement (pleuro-pulmonary group).
Results: Among the 205 patients hospitalized before the diagnosis was established, 51 (24.9%) belonged to the isolated pleurisy group. Compared to the pleuro-pulmonary group, patients in the isolated pleurisy group were younger, had fewer underlying co-morbidities, and presented more frequently with fever and chest pain. Fewer patients in the isolated pleurisy group had hypoalbuminemia (< 3.5 g/dL) and anemia. The two groups were similar with regards to PE analysis, resistance pattern, and timing of anti-tuberculous treatment. Patients who had a typical pathology of TP on pleural biopsy received anti-tuberculous treatment earlier than those who did not, and were all alive at discharge. The isolated pleurisy group had a lower in-hospital mortality rate, a shorter length of hospital stay and better short-term survival. In addition, the presence of underlying comorbidities and not receiving anti-tuberculous treatment were associated with a higher in-hospital mortality rate.
Conclusion: In culture-confirmed tuberculous pleurisy, those with pulmonary involvement were associated with a higher in-hospital mortality rate. A typical pathology for TP on pleura biopsy was associated with a better outcome.
Kohli M, Schiller I, Dendukuri N, Yao M, Dheda K, Denkinger C Cochrane Database Syst Rev. 2021; 1:CD012768.
PMID: 33448348 PMC: 8078545. DOI: 10.1002/14651858.CD012768.pub3.
Clinical significance of Glasgow Prognostic Score in patients with tuberculous pleurisy.
Kang H, Lee H, Jung J, Kim J, Kim Y, Kim S J Thorac Dis. 2019; 10(11):6077-6087.
PMID: 30622779 PMC: 6297411. DOI: 10.21037/jtd.2018.10.02.
Xpert MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.
Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger C, Schumacher S Cochrane Database Syst Rev. 2018; 8:CD012768.
PMID: 30148542 PMC: 6513199. DOI: 10.1002/14651858.CD012768.pub2.
Index-TB guidelines: Guidelines on extrapulmonary tuberculosis for India.
Sharma S, Ryan H, Khaparde S, Sachdeva K, Singh A, Mohan A Indian J Med Res. 2017; 145(4):448-463.
PMID: 28862176 PMC: 5663158. DOI: 10.4103/ijmr.IJMR_1950_16.
Corticosteroids for tuberculous pleurisy.
Ryan H, Yoo J, Darsini P Cochrane Database Syst Rev. 2017; 3:CD001876.
PMID: 28290161 PMC: 5461868. DOI: 10.1002/14651858.CD001876.pub3.